On February 24, 2023 OREGA Biotech, the biotech company committed to the discovery of novel immuno-oncology targets for cancer immunotherapy, reported the initiation of IPH5201 CD39 blocking antibody phase 2 trial (MATISSE) (Press release, OREGA BIOTECH, FEB 24, 2023, View Source [SID1234627733]). The study entitled "Phase II Multicenter, Open Label, Non-randomized Study of Neoadjuvant and Adjuvant Treatment With IPH5201 and Durvalumab in Patients With Resectable, Early-stage (II to IIIA) Non-Small Cell Lung Cancer (MATISSE)" is an open-label, single-arm multicenter study (NCT05742607). As announced in 2022 (press release), the study will enroll 70 patients treated with IPH5201 (CD39 antibody) and Durvalumab (PDL1 antibody) plus standard of care chemotherapy before surgery followed by IPH5201 and Durvalumab.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

About IPH5201 antibody

IPH5201 is a humanized CD39 blocking antibody. OREGA Biotech entered into an exclusive and worldwide License Agreement with Innate Pharma in 2016. The lead antibody has been further partnered with AstraZeneca in 2018. AstraZeneca conducted a multicenter, open-label, dose-escalation Phase 1 trial in advanced solid tumors (NCT04261075) with IPH5201 alone or in combination with durvalumab (anti PD-L1 antibody).